Martingale Asset Management LP invested $519,000 in Arcutis Biotherapeutics, Inc.

According to the company's most recent filing with the Securities and Exchange Commission, Martingale Asset Management L P grew its position in Arcutis Biotherapeutics, INC during the third quarter.

‍

The institutional investor paid around $519,00 for 27,108 shares of the company's stock.

‍

According to recent Arcutis Biotherapeutics news, Howard G. Welgus, the company's director, sold 8,500 shares of the company's stock on February 15th.

‍

This trade, according to reports, occurred.

‍

A total of 1,443,300.00 in company stock changed hands, with the average price paid for each share is $16.98. Following the transaction, the director will possess a total of 165,825 shares in the firm.

‍

These shares will be valued at roughly $2,815,708.50 based on the current market price. By clicking on the link in the previous line, you will be sent to a page where you may view the legal documents submitted to the Securities and Exchange Commission in connection with the transaction.

‍

According to recent Arcutis Biotherapeutics news, the company's director, Howard G. Welgus, sold 8,500 shares of the company's stock on February 15th.

‍

A total of 1,443,300.00 of the company's stock changed hands, with the average price paid for each share is $16.98.

‍

Upon the conclusion of the sale, the director will possess a total of 165,825 shares in the firm.

‍

Based on the current market price, these shares are worth roughly $2,815,708.50. Clicking on the link in the previous line will lead you to a page where you can view the legal documents sent to the Securities and Exchange Commission regarding the transaction.

‍

Also, on February 28th, an individual named Todd Franklin Watanabe sold 2,343 shares of the company's stock.

‍

Each share was sold for an average price of $16.17, resulting in a total selling volume of 37,886.31 dollars.

‍

The selling price for each share was found to be $16.17. After the sale, the insider was left with 374,564 shares of the business, each of which was worth about $6,056,699.88 on the date of the transaction.

‍

This website section may contain disclosures about the transaction.

‍

During the most recent fiscal quarter, 34,548 shares of company stock were sold for a total of $537,319 by business insiders.

‍

These people own 23.00% of the company's total outstanding shares.

‍

Other significant investors have lately made changes to their firm interests.

‍

Point72 Hong Kong Ltd increased its holding investment in Arcutis Biotherapeutics by 102.9% during the second quarter.

‍

Point72 Hong Kong Ltd now owns 1,197 shares of the company's stock, valued at $26,000, after purchasing 607 more shares during the last period. During the first three months of 2018, Quantbot Technologies LP spent roughly $44,000 buying more Arcutis Biotherapeutics shares.

‍

Amundi invested 114 thousand dollars in a new holding at Arcutis Biotherapeutics during the second quarter.

‍

Amundi had to learn new skills for this post. Zurcher Kantonalbank, a Swiss bank, owned 332.6% more shares of Arcutis Biotherapeutics after the third quarter than at the beginning. Zurcher Kantonalbank, a Swiss bank, currently owns 5,892 shares in the firm after acquiring an extra 4,530 shares over time.

‍

These shares are now worth $113,000 as a result of their acquisition (and counting).

‍

Amalgamated Bank boosted its stake in Arcutis Biotherapeutics by 19.5% during the third quarter, making this the final and most critical point.

‍

After the relevant time, Amalgamated Bank purchased an additional 1,079 shares, increasing its total number of shares owned to 6,612, each worth $126,000.

As trading began on Thursday, the price per share of ARQT was found to be $13.46.

‍

The company's price-to-earnings ratio is -2.38, and its beta value is 0.52.

‍

At the moment, the company's market capitalization is at $822.18 million.

‍

The current ratio to quick ratio is 11.37, and the quick ratio to current ratio is 11.57.

The debt-to-equity ratio is 0.94.

‍

Arcutis Biotherapeutics, INC's low point in the last year was $12.81, and the company's high point in the last year was $27.40.

‍

The company's moving average over the last 50 days is $15.65, and the moving average over the last 200 days is $17.69.

‍

Many research experts from various companies have recently issued remarks on the stock. Cantor Fitzgerald has reaffirmed its "overweight" rating on Arcutis Biotherapeutics shares, which was made public in a research note on March 1st.

‍

Morgan Stanley reduced its "overweight" rating and price objective on Arcutis Biotherapeutics shares to $50.00 and $51.00, respectively, in a research note released on March 1st.

‍

This adjustment occurred as a result of a fall in the share price. In a research report published on Wednesday, March 1st, Needham & Company LLC maintained their "buy" rating on Arcutis Biotherapeutics shares.

‍

They have established a price target of $46.00 for the company.

‍

Trade Algo reports that the business presently has a consensus "buy" rating and a consensus target price of $51.40. Additionally, six financial experts have given the company a buy recommendation based on the facts offered.

‍